---
title: "A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290976116.md"
description: "Helus Pharma™, a subsidiary of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), has announced that its APPROACH Phase 3 trial for HLP003, aimed at providing adjunctive treatment for major depressive disorder, has achieved over 86% enrollment. The company is progressing well towards meeting the requirements set by the FDA for the trial."
datetime: "2026-06-26T13:32:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290976116.md)
  - [en](https://longbridge.com/en/news/290976116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290976116.md)
generator: "portal-rs"
---

# A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Helus Pharma™, a subsidiary of Cybin Inc. (NASDAQ: HELP) (Cboe CA: HELP), has announced that its APPROACH Phase 3 trial for HLP003, aimed at providing adjunctive treatment for major depressive disorder, has achieved over 86% enrollment. The company is progressing well towards meeting the requirements set by the FDA for the trial.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Cybin announces annual general and special shareholder meeting](https://longbridge.com/en/news/296336431.md)
- [Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003](https://longbridge.com/en/news/293390329.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [AMLX stock clocks best day ever after positive trial data, launches $350M offering](https://longbridge.com/en/news/296273366.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**